MASLD & MASH Patient Resources
Consolidated patient guides, specialist locators, FDA-approved MASH therapy portals (Rezdiffra & Wegovy), cardiometabolic society hubs, and live clinical trials.
MASLD (formerly NAFLD) affects roughly one in three adults worldwide, and MASH (formerly NASH) is its inflammatory, scarring form. The encouraging reality in 2026 is that patients now have biopsy-free testing (FIB-4, ELF, FibroScan, MRE), two FDA-approved F2-F3 MASH medications (Rezdiffra and Wegovy), and strong evidence that modest metabolic improvements reverse early scarring.
Below you will find both our independent 37-page SLF MASLD/MASH pathway and every major medical society, federal library, advocacy group, and pharmaceutical support hub serving MASLD/MASH patients.
Verified Live Resources (92)
No resources matched that exact combination of filters.
Common Questions Patients & Families Ask
Why do some trusted websites still say NAFLD or NASH in their page titles?
Know a trusted patient resource we should add, or spotted a moved link? Steatotic Liver Foundation maintains this directory for the entire SLD community. Join our network or help keep patient navigation free for every family.